Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Re
Reuters
27 Mar
March 26 (Reuters) - Candel Therapeutics Inc :: *CANDEL THERAPEUTICS REPORTS BOTH PROLONGED MEDIAN OVERALL SURVIVAL AND LONG TAIL OF SURVIVAL IN PHASE 2A CLINICAL TRIAL OF CAN-2409 IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS NON-RESPONSIVE TO IMMUNE CHECKPOINT INHIBITOR $(ICI.AU)$ TREATMENT *CANDEL THERAPEUTICS: STATISTICALLY SIGNIFICANT IMPROVED OVERALL SURVIVAL IN NON-SQUAMOUS NSCLC VERSUS SQUAMOUS NSCLC AFTER CAN-2409 EXPERIMENTAL TREATMENT *CANDEL THERAPEUTICS INC: CAN-2409 CONTINUED TO EXHIBIT A GENERALLY FAVORABLE SAFETY AND TOLERABILITY PROFILE THROUGHOUT EXTENDED FOLLOW-UP PERIOD
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.